DNTH-103
- Generic Name
- DNTH-103
A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)
Phase 3
Recruiting
- Conditions
- Chronic Inflammatory Demyelinating Polyneuropathy
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-03-05
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Dianthus Therapeutics
- Target Recruit Count
- 480
- Registration Number
- NCT06858579
- Locations
- 🇺🇸
Clinical Study Site, Sugar Land, Texas, United States
🇺🇸Texas Locations, Houston, Texas, United States
A Clinical Study to Evaluate DNTH103 in Adults With Multifocal Motor Neuropathy
- First Posted Date
- 2024-08-05
- Last Posted Date
- 2025-03-14
- Lead Sponsor
- Dianthus Therapeutics
- Target Recruit Count
- 36
- Registration Number
- NCT06537999
- Locations
- 🇵🇱
Clinical Study Site, Katowice, Poland
A Phase 2 Study to Evaluate DNTH103 in Adults With Generalized Myasthenia Gravis (MAGIC)
Phase 2
Active, not recruiting
- Conditions
- Myasthenia Gravis, Generalized
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Dianthus Therapeutics
- Target Recruit Count
- 65
- Registration Number
- NCT06282159
- Locations
- 🇺🇸
Clincal Study Site, Tampa, Florida, United States
🇺🇸Clinical Study Site #2, Houston, Texas, United States
🇸🇪Clinical Study Site, Malmö, Sweden
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath